Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00423046

Enrollment

1106

Registered

2007-01-17

Start date

2007-01-24

Completion date

2012-05-14

Last updated

2020-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Papillomavirus, Papillomavirus Vaccines

Keywords

Vaccines, Cervical cancer, Immunogenicity, Humans, Safety, Viral infections, Human papillomavirus (HPV), Comparative study, Human papillomavirus vaccine, Adults

Brief summary

HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine (Cervarix TM) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in \> 70%, approximately, of all cervical cancers. Recently, Merck's HPV vaccine Gardasil® \[quadrivalent human papillomavirus (HPV-6,11,16,18 L1 VLP) recombinant vaccine\] has been approved by the FDA for prevention of genital tract cancers and pre-cancers and genital warts in females. Although the GSK HPV vaccine and Gardasil® have different compositions and are expected to have different efficacy profiles, each vaccine targets prevention of HPV-16 and 18 genital tract cancers and pre-cancers. Therefore, a comparison of the immunogenicity of the two vaccines is warranted. This Phase 3b study is designed to compare the immunogenicity of the GSK vaccine (HPV-16/18) to Gardasil® in healthy adult females 18-45 years of age. The Protocol Posting has been updated as the study will be extended by 3 additional years.

Detailed description

This Protocol Posting has been updated following Protocol Amendment 25, November 2010

Interventions

BIOLOGICALGSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)

Three doses administered intramuscularly at months 0, 1 and 6

BIOLOGICALGardasil ® (Merck & Co. Inc)

Three doses administered intramuscularly at months 0, 2 and 6

BIOLOGICALPlacebo

One dose administered intramuscularly at month 1 to maintain blinding

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* A woman whom the investigator believes that she or her legally acceptable representative (in the event that the subject is illiterate) can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits). * A woman between and including 18 and 45 years of age at the time of the first vaccination. * Written informed consent must be obtained from the subject prior to enrollment. * Subject must be free of obvious health problems as established by medical history and history-directed clinical examination before entering into the study. * Subject must have a negative urine pregnancy test. * Subject must be of non-childbearing potential, or if she is of child bearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series. * Subject must have an intact cervix.

Exclusion criteria

* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period up to Month 60. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned administration during the study period up to Month 60. * Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0-29) each dose of vaccine. Administration of routine vaccines up to 8 days before each dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window. * Pregnant or breastfeeding. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study. * A woman planning to become pregnant or planning to discontinue contraceptive precautions during approximately the first eight months of the study (Months 0-8). * Previous administration of components of the investigational vaccine * Previous or planned vaccination against HPV outside of this protocol. * Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination. * History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines. * Hypersensitivity to latex. * Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests. * History of significant medical conditions and currently under treatment. * Received immunoglobulins and/or blood product within 90 days preceding enrolment or planned administration during the study period up to Month 60. Enrollment will be deferred until the subject is outside of specified window. * Acute disease at the time of enrolment. Enrollment will be deferred until condition is resolved. All vaccines can be administered to persons with a minor illness * Heavy bleeding (menstruation or other) or heavy vaginal discharge in which a pelvic exam cannot be performed. Enrollment will be deferred until condition is resolved according to investigator's medical judgement.

Design outcomes

Primary

Measure	Time frame	Description
Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	At Month 7	Titers are displayed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum.

Secondary

Measure	Time frame	Description
Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	At Month 7	Other oncogenic HPV types include HPV-31 and HPV-45. The titer value (=serum dilution giving a 50 percent reduction of the signal compared to a control without serum) used as the cut-off for seroconversion was 40 for both other oncogenic types HPV-31 and HPV-45.
Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	At Month 7	Other Oncogenic Types include HPV-31 and HPV-45. Titers were measured by neutralization assay and are given as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum
Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	At Month 6, 7, 12, 18, 24, 36, 48 and 60	The titer value (=serum dilution giving a 50 percent reduction of the signal compared to a control without serum) used as the cut-off for seroconversion was 40 for both HPV-16 and HPV-18.
Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	At Month 6, 7, 12, 18, 24, 36, 48 and 60	Cut-off values assessed were greater than or equal to 8 ELISA units per milliliter (EL.U/mL) for HPV-16 and greater than or equal to 7 EL.U/mL for HPV-18.
Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	At Month 6, 7, 12, 18, 24, 36, 48 and 60	Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).
Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	At Month 6, 7, 12, 18, 24, 36 and 48	Other oncogenic types include HPV-31 and HPV-45. Cut-off values assessed were greater than or equal 59 EL.U/mL in the sera of subjects seronegative before vaccination.
Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	At Month 6, 7, 12, 18, 24, 36 and 48	Other oncogenic types include HPV-31 and HPV-45. Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).
Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	At Month 7, 12, 18, 24, 36 and 48	Number of cells were expressed as geometric mean, minimum and maximum values of specific CD4 cells producing at least 2 cytokines (CD40 Ligand, Interleukin-2, Tumor Necrosis Factor Alpha or Interferon-gamma) per million of CD4 T-cells.
Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	At Month 6, 7, 12, 18, 24, 36, 48 and 60	Titers are given as Geometric Mean Titers (GMTs). Titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum. Data for Month 7 on subjects aged 18 to 26 years are given in the outcome above as a primary outcome measure.
Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	At Month 7, 12, 18, 24, 36 and 48	HPV-16 and HPV-18 Specific Memory B Cells were measured by Enzyme-linked immunosorbent spot (ELISPOT) assay and expressed as geometric mean, minimum and maximum values of specific B-cells per million of cells.
Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	At Month 7, 12, 18, 24, 36 and 48	Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).
Number of Subjects Completing the 3-dose Vaccination Schedule	Up to Month 7	—
Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	During the 7-day period (Day 0-6) following vaccination	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. All solicited local symptoms were assessed as related to study vaccination.
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	During the 7-day period (Day 0-6) following vaccination	Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], gastrointestinal, headache, myalgia, rash and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	During the 30-day period (Day 0-29) following vaccination	Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.Grade 3 AE = AE that prevented normal activity. Related AE = AE assessed by the investigator as causally related to the study vaccination.
Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	Up to Month 7	NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSCs include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.
Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Up to Month 7	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related SAE = SAE assessed by the investigator as causally related to the study vaccination. Intensity of SAEs was not assessed.
Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	At Month 7, 12 and 18	Data were expressed as geometric mean, minimum and maximum values of specific CD8 cells producing at least 2 cytokines (CD40 Ligand, Interleukin-2, Tumor Necrosis Factor Alpha or Interferon-gamma) per million of CD8 T-cells. Analyses for further time points were not performed, as there was no response at these time points.

Countries

United States

Participant flow

Pre-assignment details

Subjects who missed Month 7 visit and/or one or more follow-up visits were permitted to attend the next scheduled follow-up visits.

Participants by arm

Arm	Count
Cervarix Group Subjects received 3 doses of GSK Biologicals human papillomavirus \[HPV\] 16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.	553
Gardasil Group Subjects received 3 doses of Gardasil® (Merck's human papillomavirus \[HPV\] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.	553
Total	1,106

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Other	340	345

Baseline characteristics

Characteristic	Cervarix Group	Gardasil Group	Total
Age, Continuous	30.3 years STANDARD_DEVIATION 8.02	30.2 years STANDARD_DEVIATION 7.78	30.25 years STANDARD_DEVIATION 7.9
Sex: Female, Male Female	553 Participants	553 Participants	1106 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	500 / 553	462 / 553
serious Total, serious adverse events	44 / 553	37 / 553

Outcome results

Primary

Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies

Titers are displayed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum.

Time frame: At Month 7

Population: Analysis was performed on subjects from the According-to-Protocol (ATP) cohort for immunogenicity aged 18 to 26 years and who were seronegative by Pseudovirion (PSV) neutralizing assay and deoxyribonucleic acid (DNA) negative for the corresponding type at baseline.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16	36791.8 titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18	16486.9 titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16	10053.1 titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18	2257.9 titer

Secondary

Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells

HPV-16 and HPV-18 Specific Memory B Cells were measured by Enzyme-linked immunosorbent spot (ELISPOT) assay and expressed as geometric mean, minimum and maximum values of specific B-cells per million of cells.

Time frame: At Month 7, 12, 18, 24, 36 and 48

Population: Results are presented by age group in subjects with detectable B-cells (\>0) at defined time points, who were HPV-16/18 seronegative (by PSV neutralizing assay), DNA negative and HPV-16/18 specific B-cell negative at baseline from a subset of the ATP cohort for immunogenicity.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 36	503.9 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 7	785.7 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 7	700.7 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 12	344.1 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 18	262.1 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 24	233.5 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 36	207.7 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 48	219.7 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 7	898.0 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 12	237.6 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 18	216.5 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 24	279.1 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 36	506.5 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 48	354.3 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 7	1476.0 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 12	363.7 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 18	301.3 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 24	492.1 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 48	364.8 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 7	313.2 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 12	152.5 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 18	137.3 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 24	255.5 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 36	391.0 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 48	124.7 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 7	433.4 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 12	172.4 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 18	202.5 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 24	151.6 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 36	161.9 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 48	366.4 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 12	459.8 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 18	436.9 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 24	576.8 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 36	376.6 cells per million B-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 48	302.4 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 12	242.8 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 48	134.2 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 48	738.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 18	74.7 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 7	358.5 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 7	163.9 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 12	192.3 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 48	91.7 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 18	325.2 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 12	63.8 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 24	440.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 24	97.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 36	505.4 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 18	76.4 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 18-26-year, Month 48	130.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 18	91.5 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 7	253.5 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 24	101.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 12	202.8 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 36	224.2 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 18	194.3 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 36	114.1 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 24	141.2 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 36	23.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 36	142.1 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 18-26-year, Month 48	118.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 27-35-year, Month 48	358.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 7	192.5 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 7	539.3 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 7	153.7 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 12	270.8 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 36-45-year, Month 24	106.6 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 18	210.2 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-18, 27-35-year, Month 12	130.4 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 24	338.0 cells per million B-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells	HPV-16, 36-45-year, Month 36	192.9 cells per million B-cells

Secondary

Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells

Number of cells were expressed as geometric mean, minimum and maximum values of specific CD4 cells producing at least 2 cytokines (CD40 Ligand, Interleukin-2, Tumor Necrosis Factor Alpha or Interferon-gamma) per million of CD4 T-cells.

Time frame: At Month 7, 12, 18, 24, 36 and 48

Population: Results are presented by age group for subjects HPV-16/18 seronegative (by PSV neutralizing assay), DNA negative and HPV-16/18 specific T-cell negative (i.e., with \< 500 cells/million cells at baseline) from a subset of the ATP cohort for immunogenicity.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 7	1285.6 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 12	1087.6 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 18	1194.4 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 24	1195.9 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 36	838.3 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 48	1272.4 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 12	664.1 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 18	1134.4 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 24	919.8 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 48	307.7 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 7	979.7 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 12	707.7 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 18	1116.8 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 24	1118.9 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 36	710.5 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 48	1247.9 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 7	998.8 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 12	716.4 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 18	844.3 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 24	793.0 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 36	622.6 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 48	927.7 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 7	924.3 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 12	416.5 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 18	710.8 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 24	575.6 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 48	643.7 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 7	815.6 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 12	384.3 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 18	949.0 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 24	807.2 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 36	337.4 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 48	764.0 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 7	990.7 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 36	431.0 cells per million CD4 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 36	265.4 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 48	388.6 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 7	729.1 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 18	264.2 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 12	421.3 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 12	405.0 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 18	309.0 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 24	355.8 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 24	323.5 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 36	211.4 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 18-26-year, Month 36	399.9 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 18	195.4 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 7	637.1 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 48	162.1 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 12	493.3 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 36	206.2 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 18	448.0 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 7	680.7 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 24	373.0 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 24	520.5 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 48	560.8 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 12	471.2 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 7	609.8 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 27-35-year, Month 36	85.9 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 12	431.3 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 18	568.4 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 18	446.1 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 36	392.1 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 24	789.3 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 24	197.4 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 36	494.2 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 27-35-year, Month 48	426.7 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-16, 36-45-year, Month 48	642.4 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 48	612.2 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 7	594.9 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 36-45-year, Month 7	212.2 cells per million CD4 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells	HPV-18, 18-26-year, Month 12	192.3 cells per million CD4 T-cells

Secondary

Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells

Data were expressed as geometric mean, minimum and maximum values of specific CD8 cells producing at least 2 cytokines (CD40 Ligand, Interleukin-2, Tumor Necrosis Factor Alpha or Interferon-gamma) per million of CD8 T-cells. Analyses for further time points were not performed, as there was no response at these time points.

Time frame: At Month 7, 12 and 18

Population: Results are presented by age group for subjects HPV-16/18 seronegative (by PSV neutralizing assay), DNA negative and HPV-16/18 specific T-cell negative (i.e., with \< 200 cells/million cells at baseline) from a subset of the ATP cohort for immunogenicity.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 18-26-year, Month 18	3.5 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 18-26-year, Month 7	5.3 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 36-45-year, Month 7	3.0 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 36-45-year, Month 12	4.6 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 18-26-year, Month 18	4.1 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 27-35-year, Month 18	3.1 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 27-35-year, Month 12	5.0 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 36-45-year, Month 18	4.1 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 27-35-year, Month 7	2.6 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 27-35-year, Month 7	2.5 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 27-35-year, Month 12	3.5 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 18-26-year, Month 7	9.3 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 36-45-year, Month 7	9.2 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 27-35-year, Month 18	2.4 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 36-45-year, Month 12	2.4 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 18-26-year, Month 12	4.6 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 36-45-year, Month 18	6.3 cells per million CD8 T-cells
Cervarix Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 18-26-year, Month 12	4.0 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 36-45-year, Month 18	4.5 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 18-26-year, Month 12	2.8 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 18-26-year, Month 18	4.5 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 27-35-year, Month 7	5.1 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 27-35-year, Month 12	3.8 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 27-35-year, Month 18	8.6 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 36-45-year, Month 12	4.0 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 36-45-year, Month 18	8.9 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 18-26-year, Month 7	3.0 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 18-26-year, Month 12	3.4 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 18-26-year, Month 7	3.2 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-16, 36-45-year, Month 7	6.1 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 27-35-year, Month 18	7.1 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 18-26-year, Month 18	4.3 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 27-35-year, Month 7	3.6 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 27-35-year, Month 12	4.6 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 36-45-year, Month 7	3.4 cells per million CD8 T-cells
Gardasil Group	Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells	HPV-18, 36-45-year, Month 12	6.8 cells per million CD8 T-cells

Secondary

Number of Subjects Completing the 3-dose Vaccination Schedule

Time frame: Up to Month 7

Population: The number of subjects completing the 3-dose vaccination schedule was defined as the number of subjects who received the 3 active doses (placebo administrations are not reflected).

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Completing the 3-dose Vaccination Schedule	468 Participants
Gardasil Group	Number of Subjects Completing the 3-dose Vaccination Schedule	467 Participants

Secondary

Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], gastrointestinal, headache, myalgia, rash and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame: During the 7-day period (Day 0-6) following vaccination

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Fever	76 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria	24 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal symptoms	10 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Headache	250 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache	19 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia	114 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia	10 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia	145 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria	1 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Rash	25 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia	102 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash	0 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue	230 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria	26 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Fever	59 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue	262 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal symptoms	134 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia	13 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Headache	209 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever	2 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia	132 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue	30 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Rash	19 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal symptoms	172 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria	15 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal symptoms	139 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia	103 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia	8 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Rash	11 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia	81 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue	209 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Fever	58 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Headache	220 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Rash	18 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria	21 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia	3 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue	12 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever	0 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal symptoms	12 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache	20 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash	1 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria	2 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia	74 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue	181 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Fever	46 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal symptoms	106 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Headache	187 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia	90 Participants

Secondary

Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. All solicited local symptoms were assessed as related to study vaccination.

Time frame: During the 7-day period (Day 0-6) following vaccination

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Grade 3 Pain	91 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Any Swelling	191 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Grade 3 Redness	3 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Any Redness	232 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Grade 3 Swelling	5 Participants
Cervarix Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Any Pain	487 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Grade 3 Swelling	3 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Any Pain	375 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Any Swelling	114 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Grade 3 Pain	18 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Grade 3 Redness	0 Participants
Gardasil Group	Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms	Any Redness	134 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSCs include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.

Time frame: Up to Month 7

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	14 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	164 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	13 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	148 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Time frame: Up to Month 60

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	Any NOCD(s)	39 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	Any MSC(s)	259 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	Any NOCD(s)	43 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	Any MSC(s)	226 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Time frame: Up to Month 48

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCDs	33 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSCs	251 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSCs	216 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCDs	33 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.

Time frame: Up To Month 36

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	27 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	239 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	29 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	205 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Time frame: Up To Month 24

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	20 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	221 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	21 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	192 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Time frame: Up To Month 18

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	20 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	210 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	21 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	185 Participants

Secondary

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Time frame: Up To Month 12

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	181 Participants
Cervarix Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	14 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	NOCD(s)	17 Participants
Gardasil Group	Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)	MSC(s)	168 Participants

Secondary

Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value

The titer value (=serum dilution giving a 50 percent reduction of the signal compared to a control without serum) used as the cut-off for seroconversion was 40 for both HPV-16 and HPV-18.

Time frame: At Month 6, 7, 12, 18, 24, 36, 48 and 60

Population: Analysis was performed by age group on subjects from the According-to-Protocol (ATP) cohort for immunogenicity who were seronegative by Pseudovirion neutralizing assay and deoxyribonucleic acid (DNA) negative for the corresponding type at baseline.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 36	63 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 7	104 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 12	101 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 18	100 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 36	60 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 48	54 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 60	35 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 6	90 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 7	90 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 12	91 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 18	87 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 24	84 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 6	104 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 48	54 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 60	43 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 6	95 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 18	90 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 24	87 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 36	61 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 48	50 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 60	46 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 6	117 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 7	118 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 12	112 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 18	109 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 24	106 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 36	64 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 48	59 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 60	39 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 6	99 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 18	101 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 24	98 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 60	53 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 12	104 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 36	69 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 48	59 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 24	97 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 7	96 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 12	89 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 7	102 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 12	104 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 36	75 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 48	66 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 6	107 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 7	110 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 18	102 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 24	99 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 60	55 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 18	91 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 6	101 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 18	106 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 7	103 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 24	68 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 12	99 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 24	92 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 24	87 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 48	34 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 36	61 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 36	60 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 48	56 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 7	83 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 18-26-year, Month 60	39 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 48	57 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 6	83 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 18	79 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 7	85 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 60	40 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 12	84 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 12	83 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 18	82 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 6	84 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 24	77 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 12	92 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 36	49 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 6	78 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 48	49 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 18	74 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 27-35-year, Month 60	28 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 7	99 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 6	81 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 60	38 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 18	82 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 60	22 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 24	80 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 24	68 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 36	57 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 12	90 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 48	53 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 7	91 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-16, 36-45-year, Month 60	45 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 36	45 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 6	121 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 27-35-year, Month 36	43 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 7	131 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 36-45-year, Month 48	44 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value	Anti-HPV-18, 18-26-year, Month 12	122 Participants

Secondary

Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value

Other oncogenic HPV types include HPV-31 and HPV-45. The titer value (=serum dilution giving a 50 percent reduction of the signal compared to a control without serum) used as the cut-off for seroconversion was 40 for both other oncogenic types HPV-31 and HPV-45.

Time frame: At Month 7

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-31, 27-35-year	59 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-45, 18-26-year	35 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-45, 27-35-year	21 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-31, 18-26-year	90 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-31, 36-45-year	68 Participants
Cervarix Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-45, 36-45-year	28 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-45, 27-35-year	7 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-31, 27-35-year	32 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-31, 36-45-year	39 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-31, 18-26-year	60 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-45, 18-26-year	4 Participants
Gardasil Group	Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value	Anti-HPV-45, 36-45-year	10 Participants

Secondary

Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Other oncogenic types include HPV-31 and HPV-45. Cut-off values assessed were greater than or equal 59 EL.U/mL in the sera of subjects seronegative before vaccination.

Time frame: At Month 6, 7, 12, 18, 24, 36 and 48

Population: Analysis was performed by age group on subjects from the ATP cohort for immunogenicity who were seronegative (by ELISA) and DNA negative for the corresponding type at baseline.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 36	30 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 12	101 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 6	42 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 18	90 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 48	22 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 24	89 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 18	80 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 36	50 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 6	45 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 48	37 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 7	80 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 6	62 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 7	76 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 7	85 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 36	44 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 12	81 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 18	48 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 18	68 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 12	72 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 24	68 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 12	69 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 36	45 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 12	89 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 48	36 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 24	49 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 6	58 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 18	52 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 7	83 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 36	33 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 12	73 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 48	37 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 18	56 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 48	20 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 24	51 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 24	50 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 36	31 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 6	95 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 48	28 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 24	77 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 6	75 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 7	109 Participants
Cervarix Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 7	98 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 48	34 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 12	103 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 18	71 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 24	62 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 36	42 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 48	32 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 6	76 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 7	81 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 12	80 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 18	53 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 24	48 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 36	29 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 48	23 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 6	70 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 7	78 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 18	56 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 12	75 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 24	51 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 36	38 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 48	32 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 6	104 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 7	109 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 12	105 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 18	77 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 24	68 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 36	46 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 7	111 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 6	83 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 7	86 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 12	84 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 18	64 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 24	56 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 36	29 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 48	21 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 6	76 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 7	80 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 12	80 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 18	67 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 24	61 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 36	41 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 48	32 Participants
Gardasil Group	Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 6	104 Participants

Secondary

Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Cut-off values assessed were greater than or equal to 8 ELISA units per milliliter (EL.U/mL) for HPV-16 and greater than or equal to 7 EL.U/mL for HPV-18.

Time frame: At Month 6, 7, 12, 18, 24, 36, 48 and 60

Population: Analysis was performed by age group on subjects from the ATP cohort for immunogenicity who were seronegative (by ELISA) and DNA negative for the corresponding type at baseline.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 48	43 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 24	81 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 36	50 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 48	46 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 60	31 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 6	57 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 12	57 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 18	54 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 24	52 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 36	41 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 60	28 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 6	64 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 7	64 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 12	59 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 18	61 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 24	58 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 48	35 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 60	31 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 6	95 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 36	49 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 60	31 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 6	71 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 12	72 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 18	69 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 36	54 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 48	50 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 60	39 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 6	74 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 12	69 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 18	69 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 24	67 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 36	51 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18 36-45-year, Month 60	39 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 6	91 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 12	87 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 18	84 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 7	57 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 48	37 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 36	42 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 7	95 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 12	92 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 18	90 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 24	87 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 48	47 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 7	71 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 24	68 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 7	74 Participants
Cervarix Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 7	91 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 36	41 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 48	36 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 24	73 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 24	50 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 36	53 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 60	23 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 48	47 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 48	52 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 60	35 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 7	68 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 6	55 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 6	99 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 12	57 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 12	70 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 18	53 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 6	66 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 24	51 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 18	71 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 36	35 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 48	36 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 7	100 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 60	20 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 24	67 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 6	52 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 6	67 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 7	52 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 48	51 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 12	53 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 12	97 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 18	52 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18 36-45-year, Month 60	41 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 36	36 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 36	51 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 48	36 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 6	85 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 60	31 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 7	86 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 24	82 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 18	87 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 12	81 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 60	38 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 24	61 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 7	67 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 18	76 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 12	68 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 36	59 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 18	64 Participants
Gardasil Group	Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 7	56 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related SAE = SAE assessed by the investigator as causally related to the study vaccination. Intensity of SAE(s) was not assessed. Note: SAEs were unblinded at the Month 60 analysis.

Time frame: Up to Month 60

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	44 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	37 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Time frame: Up to Month 7

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	6 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	7 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Time frame: Up to Month 12

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	12 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	20 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Time frame: Up to Month 18

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	14 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	20 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Time frame: Up to Month 24

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	23 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	22 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Time frame: Up to Month 36

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	30 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	28 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Time frame: Up to Month 48

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	37 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Any SAE(s)	34 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)	Related SAE(s)	1 Participants

Secondary

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.Grade 3 AE = AE that prevented normal activity. Related AE = AE assessed by the investigator as causally related to the study vaccination.

Time frame: During the 30-day period (Day 0-29) following vaccination

Population: Analyses were performed on subjects with available data within the Total Vaccinated cohort, which included subjects with at least one vaccine administration.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AEs	235 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AEs	41 Participants
Cervarix Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AEs	70 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AEs	202 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AEs	37 Participants
Gardasil Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AEs	63 Participants

Secondary

Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Other oncogenic types include HPV-31 and HPV-45. Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).

Time frame: At Month 6, 7, 12, 18, 24, 36 and 48

Population: Analysis was performed by age group on subjects from the ATP cohort for immunogenicity who were seronegative (by ELISA) and DNA negative for the corresponding type at baseline.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 36	74.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 18	231.3 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 24	192.9 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 48	99.8 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 48	64.4 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 48	124.7 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 7	720.6 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 6	88.4 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 12	212.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 7	588.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 18	135.3 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 7	687.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 24	125.9 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 12	357.0 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 36	94.3 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 12	197.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 7	634.3 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 12	166.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 12	196.3 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 18	109.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 18	121.7 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 24	214.8 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 24	114.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 48	82.8 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 24	108.8 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 18	106.0 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 6	69.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 36	94.4 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 12	348.0 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 7	1245.8 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 18	216.2 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 48	67.4 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 36	140.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 24	99.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 6	103.3 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 48	79.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 6	155.4 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 6	103.0 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 36	169.2 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 7	1248.1 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 36	85.5 EL.U/mL
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 6	108.5 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 36	94.7 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 6	230.0 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 7	865.9 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 12	265.0 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 18	115.1 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 24	108.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 36	94.0 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 7	602.7 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 12	217.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 18	95.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 24	86.7 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 36	69.2 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 48	59.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 6	223.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 7	649.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 12	243.5 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 18	122.9 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 24	110.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 36	92.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 36-45-year, Month 48	71.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 6	242.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 7	1103.5 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 18	127.1 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 48	75.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 6	260.7 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 7	828.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 12	242.3 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 18	102.0 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 24	100.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 36	73.5 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 7	985.1 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 12	298.2 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 18	141.6 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 48	74.3 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 18-26-year, Month 48	75.7 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-31, 27-35-year, Month 6	235.9 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 12	277.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 24	114.0 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 18-26-year, Month 36	95.2 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 27-35-year, Month 48	60.2 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 6	258.8 EL.U/mL
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-45, 36-45-year, Month 24	122.7 EL.U/mL

Secondary

Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay

Other Oncogenic Types include HPV-31 and HPV-45. Titers were measured by neutralization assay and are given as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum

Time frame: At Month 7

Population: Analysis was performed by age group on subjects from the According-to-Protocol (ATP) cohort for immunogenicity with titer greater than or equal to 40 ED50 and who were seronegative by Pseudovirion neutralizing assay and deoxyribonucleic acid (DNA) negative for the corresponding type at baseline.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-45, 36-45-year	157.6 titer
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-31, 27-35-year	369.6 titer
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-31, 36-45-year	231.0 titer
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-45, 18-26-year	129.7 titer
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-45, 27-35-year	144.1 titer
Cervarix Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-31, 18-26-year	387.3 titer
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-45, 27-35-year	379.9 titer
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-31, 18-26-year	143.2 titer
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-45, 18-26-year	86.5 titer
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-31, 27-35-year	191.8 titer
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-45, 36-45-year	79.0 titer
Gardasil Group	Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay	Anti-HPV-31, 36-45-year	198.5 titer

Secondary

Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).

Time frame: At Month 6, 7, 12, 18, 24, 36, 48 and 60

Population: Analysis was performed by age group on subjects from the ATP cohort for immunogenicity who were seronegative (by ELISA) and DNA negative for the corresponding type at baseline.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 18	501.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 60	430.3 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 24	390.5 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 48	1169.1 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 6	538.7 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 60	231.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 24	932.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 6	331.1 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 7	4246.6 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 7	2709.6 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 18	2266.3 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 12	1477.9 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 18	454.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 6	536.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 24	345.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 7	5076.9 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 36	276.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 36	582.1 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 48	231.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 7	3789.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 60	242.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 7	8864.0 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 48	449.7 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 12	3332.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 36	1373.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 60	1196.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 60	451.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 6	414.0 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 12	1978.0 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 36	746.3 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 6	314.6 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 48	608.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 24	1771.9 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 60	602.7 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 12	1521.7 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 7	2726.3 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 18	905.0 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 48	462.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 24	713.9 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 36	540.0 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 18	825.0 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 12	892.4 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 24	649.2 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 36	341.7 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 18	1177.3 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 48	304.7 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 12	838.8 EL.U/mL
Cervarix Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 6	827.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 60	41.0 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 6	889.3 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 12	1137.3 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 18	560.1 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 24	419.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 36	297.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 6	715.8 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 7	2203.1 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 12	769.2 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 18	384.0 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 60	155.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 6	690.4 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 7	2064.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 24	308.4 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 36	237.1 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 48	225.9 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 60	199.0 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 6	155.4 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 7	756.8 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 12	194.0 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 24	70.1 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 36	61.5 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 48	55.1 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 60	49.6 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 6	128.6 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 7	503.4 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 12	130.4 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 18	55.0 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 24	46.4 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 48	30.6 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 60	30.9 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 6	131.3 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 7	636.2 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 12	185.0 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 18	85.8 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 24	66.9 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 36	53.5 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 36-45-year, Month 48	47.8 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 7	3248.8 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 48	247.1 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 18-26-year, Month 60	231.9 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 24	300.6 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 36	201.9 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 27-35-year, Month 48	188.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 12	722.2 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-16, 36-45-year, Month 18	382.7 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 18-26-year, Month 18	89.6 EL.U/mL
Gardasil Group	Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)	Anti-HPV-18, 27-35-year, Month 36	39.2 EL.U/mL

Secondary

Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies

Titers are given as Geometric Mean Titers (GMTs). Titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum. Data for Month 7 on subjects aged 18 to 26 years are given in the outcome above as a primary outcome measure.

Time frame: At Month 6, 7, 12, 18, 24, 36, 48 and 60

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 12	3032.4 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 12	14524.7 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 18	6000.3 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 24	5184.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 48	3900.9 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 60	4117.8 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 6	1263.1 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 7	23907.9 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 18	2907.9 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 24	2269.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 36	1897.6 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 48	2046.3 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 60	1925.3 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 6	1729.8 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 12	7110.4 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 18	2344.0 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 24	2058.5 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 6	686.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 12	4472.4 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 18	2256.1 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 24	1652.0 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 36	1593.7 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 48	1710.9 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 6	429.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 7	9501.6 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 12	2266.3 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 24	1028.4 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 36	942.8 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 48	982.4 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 60	967.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 6	618.8 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 18	1426.7 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 24	1040.0 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 36	903.5 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 48	784.5 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 60	816.6 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 36	3844.7 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 12	7419.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 7	17301.5 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 36	1794.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 48	2081.4 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 60	1784.5 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 60	1522.9 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 18	1302.2 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 7	9845.5 Titer
Cervarix Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 6	1627.9 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 7	1438.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 6	1592.4 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 6	175.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 12	3265.2 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 48	91.5 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 18	1182.7 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 7	1043.0 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 60	764.9 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 48	750.4 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 12	280.3 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 60	529.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 18	133.3 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 6	1014.1 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 60	105.3 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 7	4958.4 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 24	116.2 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 18	689.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 24	893.5 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 36	101.9 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 36	501.7 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 36	823.7 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 48	677.6 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 48	76.9 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 60	346.4 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 18-26-year, Month 36	653.2 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 7	7634.4 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 27-35-year, Month 60	74.4 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 12	2678.2 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 6	168.7 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 18	994.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 12	433.9 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 24	874.7 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 48	1018.7 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 12	1755.9 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 6	234.1 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 18	181.5 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 12	595.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 27-35-year, Month 24	618.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 18	249.3 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 24	135.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 24	175.1 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-16, 36-45-year, Month 6	1916.5 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 36	127.8 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 36-45-year, Month 36	103.2 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 48	139.0 Titer
Gardasil Group	Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies	Anti-HPV-18, 18-26-year, Month 60	126.2 Titer

Secondary

Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)

Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).

Time frame: At Month 7, 12, 18, 24, 36 and 48

Population: Analyses were done on those subjects from the ATP cohort for immunogenicity for whom CVS samples with less than 200 erythrocytes per microliter were available.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 7	88.6 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 12	129.7 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 12	59.0 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 24	85.0 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 18	33.2 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 7	168.9 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 24	43.9 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 36	57.1 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 36	24.3 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 18	96.0 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 48	16.6 EL.U/mL
Cervarix Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 48	32.7 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 48	20.2 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 18	52.8 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 48	72.2 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 7	90.7 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 24	45.1 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 36	48.8 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 7	43.4 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 12	29.1 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 18	16.4 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 24	21.5 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-18, Month 36	23.3 EL.U/mL
Gardasil Group	Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)	Anti-HPV-16, Month 12	46.8 EL.U/mL

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies

Number of HPV-16 and HVP-18 Specific B-cells Per Million B Cells

Number of HPV-16 and HVP-18 Specific CD4 Cells Producing at Least 2 Different Cytokines Per Million of CD4 T Cells

Number of HPV-16 and HVP-18 Specific CD8 Cells Producing at Least 2 Different Cytokines Per Million of CD8 T Cells

Number of Subjects Completing the 3-dose Vaccination Schedule

Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms

Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)

Number of Subjects With Antibody Titers (Neutralizing Assay) Against Human Papilloma Virus 16 (Anti-HPV-16) and Human Papilloma Virus 18 (Anti-HPV-18) Greater Than or Equal to the Cut-off Value

Number of Subjects With Antibody Titers (Neutralizing Assay) Against Other Oncongenic HPV Types Greater Than or Equal to the Cut-off Value

Number of Subjects With Antibody Titers to Other Oncogenic HPV Types Greater Than or Equal to a Cut-off Value, Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibody Titers Above Cut-off Values, Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Titers of Antibodies to Other Oncogenic HPV Types Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Titers of Antibodies to Other Oncogenic HPV Types Measured by Neutralization Assay

Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)

Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies

Titers of HPV-16 IgG and HPV-18 IgG (by ELISA) in Cervico-vaginal Secretions (CVS)